{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T22:57:13Z","timestamp":1769209033223,"version":"3.49.0"},"update-to":[{"DOI":"10.1002\/14651858.cd000209.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2018,1,17]],"date-time":"2018-01-17T00:00:00Z","timestamp":1516147200000}}],"reference-count":114,"publisher":"Wiley","issue":"9","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd000209.pub3","type":"journal-article","created":{"date-parts":[[2018,1,17]],"date-time":"2018-01-17T11:41:37Z","timestamp":1516189297000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Vitamin E for antipsychotic-induced tardive dyskinesia"],"prefix":"10.1002","volume":"2019","author":[{"given":"Karla","family":"Soares-Weiser","sequence":"first","affiliation":[{"name":"Cochrane; Editorial & Methods Department; St Albans House, 57 - 59 Haymarket London UK SW1Y 4QX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Maayan","sequence":"additional","affiliation":[{"name":"Independent consultant; London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanna","family":"Bergman","sequence":"additional","affiliation":[{"name":"Cochrane; Cochrane Response; St Albans House 57-59 Haymarket London UK SW1Y 4QX"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,1,17]]},"reference":[{"key":"10.1002\/14651858.CD000209.pub3-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/S0006-3223(97)00027-9","article-title":"Long-term treatment effects of vitamin E for tardive dyskinesia","volume":"43","author":"Adler","year":"1998","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD000209.pub3-BIB0002|cit2","unstructured":"Adler LA Peselow E Angrist B Duncan E Lee M Rosenthal M Vitamin E in tardive dyskinesia: effects of longer term treatment Proceedings of the 31st Annual Meeting of the American College of Neuropsychopharmacology; 1992 Dec 14-18; San Juan, Puerto Rico 1992"},{"key":"10.1002\/14651858.CD000209.pub3-BIB0003|cit3","first-page":"371","article-title":"Vitamin E in tardive dyskinesia: time course of effect after placebo substitution","volume":"29","author":"Adler","year":"1993","journal-title":"Psychopharmacology Bulletin"},{"issue":"9","key":"10.1002\/14651858.CD000209.pub3-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1176\/ajp.150.9.1405","article-title":"Vitamin E treatment of tardive dyskinesia","volume":"150","author":"Adler","year":"1993","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD000209.pub3-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1001\/archpsyc.56.9.836","article-title":"Vitamin E treatment for tardive dyskinesia","volume":"56","author":"Adler","year":"1999","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD000209.pub3-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/0006-3223(94)91073-1","article-title":"Vitamin E treatment of TD: development of a VA cooperative study","volume":"35","author":"Adler","year":"1994","journal-title":"Biological Psychiatry"},{"issue":"18","key":"10.1002\/14651858.CD000209.pub3-BIB0007|cit7","first-page":"809","article-title":"Vitamin E is ineffective in treatment of late dyskinesias","volume":"90","author":"Bridler","year":"2001","journal-title":"Praxis"},{"key":"10.1002\/14651858.CD000209.pub3-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s002130050320","article-title":"Reliability of an instrumental assessment of tardive dyskinesia: results from VA Cooperative Study #394","volume":"132","author":"Caligiuri","year":"1997","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD000209.pub3-BIB0009|cit9","first-page":"59","article-title":"Interrater reliability issues in multicentric trials, part II: statistical procedures used in Department of Veterans Affairs Cooperative Study #394","volume":"33","author":"Edson","year":"1997","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1002\/14651858.CD000209.pub3-BIB0010|cit10","first-page":"861","article-title":"Whither vitamin E and tardive dyskinesia?","volume":"43","author":"Lohr","year":"1998","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD000209.pub3-BIB0011|cit11","first-page":"53","article-title":"Interrater reliability issues in multicentric trials, part I: theoretical concepts and operational procedures used in Department of Veterans Affairs Cooperative Study 394","volume":"33","author":"Tracy","year":"1997","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1002\/14651858.CD000209.pub3-BIB0012|cit12","first-page":"124","article-title":"Vitamin E in the treatment of tardive dyskinesia","volume":"39","author":"Akhtar","year":"1993","journal-title":"Journal of Postgraduate Medicine"},{"key":"10.1002\/14651858.CD000209.pub3-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1176\/ajp.151.6.925","article-title":"Effectiveness of vitamin E for treatment of long-term tardive dyskinesia","volume":"151","author":"Dabiri","year":"1994","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD000209.pub3-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/00004850-199705000-00008","article-title":"Lack of effect of vitamin E on serum creatine phosphokinase in patients with long-term tardive dyskinesia","volume":"12","author":"Dorevitch","year":"1997","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD000209.pub3-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S0006-3223(96)00367-8","article-title":"Treatment of long-term tardive dyskinesia with vitamin E","volume":"41","author":"Dorevitch","year":"1997","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD000209.pub3-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1176\/ajp.149.6.773","article-title":"Treatment of tardive dyskinesia with vitamin E","volume":"149","author":"Egan","year":"1992","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD000209.pub3-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1176\/ajp.147.4.505","article-title":"Vitamin E in the treatment of tardive dyskinesia","volume":"147","author":"Elkashef","year":"1990","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD000209.pub3-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/00005053-199402000-00009","article-title":"Vitamin E in the treatment of tardive dyskinesia: a replication study","volume":"182","author":"Lam","year":"1994","journal-title":"Journal of Nervous and Mental Diseases"},{"key":"10.1002\/14651858.CD000209.pub3-BIB0019|cit19","first-page":"167","article-title":"A double-blind placebo-controlled study of vitamin E treatment of tardive dyskinesia","volume":"57","author":"Lohr","year":"1996","journal-title":"Journal of Clinical Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD000209.pub3-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/00004850-199807000-00001","article-title":"Vitamin E in the treatment of tardive dyskinesia: a preliminary study over seven months at different doses","volume":"13","author":"Sajjad","year":"1998","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD000209.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1017\/S0924933800002625","article-title":"Treatment of tardive dyskinesias with vitamin E","volume":"6","author":"Schmidt","year":"1991","journal-title":"European Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD000209.pub3-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/01.jcp.0000104912.75206.2b","article-title":"The effect of vitamin E treatment on tardive dyskinesia and blood superoxide dismutase: a double-blind placebo-controlled trial","volume":"24","author":"Zhang","year":"2004","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"6","key":"10.1002\/14651858.CD000209.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0924-977X(99)00015-2","article-title":"The effect of vitamin E addition to acute neuroleptic treatment on the emergence of extrapyramidal side effects in schizophrenic patients: an open label study","volume":"9","author":"Dorfman-Etrog","year":"1999","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD000209.pub3-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/0920-9964(92)90164-Z","article-title":"Alpha-tocopherol in the treatment of tardive dyskinesia","volume":"6","author":"Junker","year":"1992","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD000209.pub3-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1749-6632.1989.tb14918.x","article-title":"Possible involvement of free radicals in neuroleptic induced movement disorders","volume":"570","author":"Cadet","year":"1989","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"8538","key":"10.1002\/14651858.CD000209.pub3-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S0140-6736(87)92878-9","article-title":"Alpha-tocopherol in tardive dyskinesia [letter]","volume":"1","author":"Lohr","year":"1987","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD000209.pub3-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1093\/schbul\/14.2.291","article-title":"Vitamin E in the treatment of tardive dyskinesia: the possible involvement of free radical mechanisms","volume":"14","author":"Lohr","year":"1988","journal-title":"Schizophrenia Bulletin"},{"issue":"8","key":"10.1002\/14651858.CD000209.pub3-BIB0028|cit28","first-page":"795","article-title":"Tardive dyskinesia","volume":"44","author":"Peet","year":"1993","journal-title":"Hospital and Community Psychiatry"},{"key":"10.1002\/14651858.CD000209.pub3-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/00004850-199300830-00003","article-title":"Tardive dyskinesia, lipid peroxidation and sustained amelioration with vitamin E treatment","volume":"8","author":"Peet","year":"1993","journal-title":"International Clinical Psychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD000209.pub3-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/BF02684961","article-title":"Calcium channel blockers and vitamin E for tardive dyskinesia in adults with mental retardation","volume":"7","author":"Ricketts","year":"1995","journal-title":"Journal of Developmental and Physical Disabilities"},{"issue":"2","key":"10.1002\/14651858.CD000209.pub3-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/JCP.0b013e31819a6aa2","article-title":"Comparing the effects of high-dose vitamin E with those of placebo on insulin resistance in patients with schizophrenia treated with olanzapine","volume":"29","author":"Salmasi","year":"2009","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD000209.pub3-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1176\/ajp.149.3.391","article-title":"Vitamin E in the treatment of tardive dyskinesia: a double-blind placebo-controlled study","volume":"149","author":"Shriqui","year":"1992","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD000209.pub3-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1097\/00005053-199206000-00012","article-title":"Alpha-tocopherol treatment for tardive dyskinesia","volume":"180","author":"Spivak","year":"1992","journal-title":"Journal of Nervous and Mental Disease"},{"issue":"6","key":"10.1002\/14651858.CD000209.pub3-BIB0034|cit34","first-page":"311 20","article-title":"Vitamin E in the management of drug induced tardive dyskinesia: a double-blind randomized clinical trial","volume":"4","author":"Kar-Ahmadi","year":"2002","journal-title":"Journal of Research in Medical Sciences"},{"key":"10.1002\/14651858.CD000209.pub3-BIB0035|cit35","unstructured":"ISRCTN14688109 Investigation of the potential beneficial effects of cannabidiol in the treatment of tardive dyskinesia http:\/\/www.isrctn.com 2015"},{"issue":"4","key":"10.1002\/14651858.CD000209.pub3-BIB0036|cit36","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000203.pub3","article-title":"Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia","author":"Alabed","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7066","key":"10.1002\/14651858.CD000209.pub3-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/bmj.313.7066.1200","article-title":"Detecting skewness from summary information","volume":"313","author":"Altman","year":"1996","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD000209.pub3-BIB0038|cit38","volume-title":"Tardive Dyskinesia: A Task Force Report of the American Psychiatric Association","author":"American Psychiatric Association","year":"1992"},{"key":"10.1002\/14651858.CD000209.pub3-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2125.1991.tb05604.x","article-title":"Should we cross off the crossover?","volume":"32","author":"Armitage","year":"1991","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD000209.pub3-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"Westminster Medical School HHES. A rating scale for drug-induced akathisia","volume":"154","author":"Barnes","year":"1989","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD000209.pub3-BIB0041|cit41","doi-asserted-by":"crossref","DOI":"10.1016\/B978-0-12-079035-7.50021-X","article-title":"The side-effects of antipsychotic drugs. I. CNS and neuromuscular effects","volume-title":"Antipsychotic Drugs and their Side-Effects","author":"Barnes","year":"1993"},{"issue":"8","key":"10.1002\/14651858.CD000209.pub3-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.1996.03540080059030","article-title":"Improving the quality of reporting of randomized controlled trials. The CONSORT statement","volume":"276","author":"Begg","year":"1996","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD000209.pub3-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1192\/bjp.144.5.498","article-title":"Tardive dyskinesia: fluctuating patient or fluctuating rater","volume":"144","author":"Bergen","year":"1984","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD000209.pub3-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1192\/bjp.154.4.523","article-title":"The course of tardive dyskinesia in patients on long-term neuroleptics","volume":"154","author":"Bergen","year":"1989","journal-title":"British Journal of Psychiatry"},{"issue":"43","key":"10.1002\/14651858.CD000209.pub3-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta21430","article-title":"Systematic review of interventions for treating or preventing antipsychotic-induced tardive dyskinesia","volume":"21","author":"Bergman","year":"2017 Aug","journal-title":"Health Technol Assess"},{"issue":"3","key":"10.1002\/14651858.CD000209.pub3-BIB0046|cit46","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000205.pub2","article-title":"Benzodiazepines for neuroleptic-induced tardive dyskinesia","author":"Bhoopathi","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD000209.pub3-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/bmj.315.7108.600","article-title":"Statistics notes. Trials randomised in clusters","volume":"315","author":"Bland","year":"1997","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD000209.pub3-BIB0048|cit48","first-page":"405","article-title":"The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use","volume":"54","author":"Boissel","year":"1999","journal-title":"Therapie"},{"key":"10.1002\/14651858.CD000209.pub3-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1749-6632.1989.tb14918.x","article-title":"Possible involvement of free radical in neuroleptic-induced movement disorders","volume":"570","author":"Cadet","year":"1989","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1002\/14651858.CD000209.pub3-BIB0050|cit50","article-title":"Tardive dyskinesia: pathophysiology","volume-title":"Psychopharmacology. The Fourth Generation of Progress","author":"Casey","year":"1994"},{"key":"10.1002\/14651858.CD000209.pub3-BIB0051|cit51","doi-asserted-by":"crossref","unstructured":"Chouinard G Chouinard VA Atypical antipsychotics: CATIE study, drug-induced movement disorder and resulting iatrogenic psychiatric-like symptoms, supersensitivity rebound psychosis and withdrawal discontinuation syndromes Psychotherapy and Psychosomatics 2008 69 77","DOI":"10.1159\/000112883"},{"issue":"1","key":"10.1002\/14651858.CD000209.pub3-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s13311-013-0222-5","article-title":"Tardive Dyskinesia: therapeutic options for an increasingly common disorder","volume":"11","author":"Cloud","year":"2014","journal-title":"Neurotherapeutics"},{"issue":"3","key":"10.1002\/14651858.CD000209.pub3-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1176\/appi.ajp.161.3.414","article-title":"Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies","volume":"161","author":"Correll","year":"2004","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD000209.pub3-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/YCO.0b013e3282f53132","article-title":"Tardive dyskinesia and new antipsychotics","volume":"21","author":"Correll","year":"2008","journal-title":"Current Opinion in Psychiatry"},{"key":"10.1002\/14651858.CD000209.pub3-BIB0055|cit55","unstructured":"Deeks J Issues in the selection for meta-analyses of binary data Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town Cape Town The Cochrane Collaboration 2000"},{"key":"10.1002\/14651858.CD000209.pub3-BIB0056|cit56","unstructured":"Deeks JJ Higgins JPT Altman DG editor(s) Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.handbook.cochrane.org"},{"issue":"6","key":"10.1002\/14651858.CD000209.pub3-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/BF02599201","article-title":"The unit of analysis error in studies about physicians' patient care behavior","volume":"7","author":"Divine","year":"1992","journal-title":"Journal of General Internal Medicine"},{"key":"10.1002\/14651858.CD000209.pub3-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1002\/sim.1301","article-title":"Issues in the meta-analysis of cluster randomized trials","volume":"21","author":"Donner","year":"2002","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD000209.pub3-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD000209.pub3-BIB0060|cit60","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000458.pub2","article-title":"Non-neuroleptic catecholaminergic drugs for neuroleptic-induced tardive dyskinesia","author":"El-Sayeh","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD000209.pub3-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"issue":"11","key":"10.1002\/14651858.CD000209.pub3-BIB0062|cit62","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000206.pub3","article-title":"Calcium channel blockers for neuroleptic-induced tardive dyskinesia","author":"Essali","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD000209.pub3-BIB0063|cit63","first-page":"25","article-title":"Progress in the treatment of tardive dyskinesia: theory and practice","volume":"44","author":"Feltner","year":"1993","journal-title":"Hospital and Community Psychiatry"},{"key":"10.1002\/14651858.CD000209.pub3-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1212\/WNL.56.6.805","article-title":"The course of tardive dyskinesia and parkinsonism in psychiatric inpatients: 14-year follow-up","volume":"56","author":"Fernandez","year":"2001","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD000209.pub3-BIB0065|cit65","article-title":"The crossover study","volume-title":"The Design and Analysis of Clinical Experiments","author":"Fleiss","year":"1984"},{"issue":"7","key":"10.1002\/14651858.CD000209.pub3-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jclinepi.2005.06.006","article-title":"Imputing missing standard deviations in meta-analyses can provide accurate results","volume":"59","author":"Furukawa","year":"2006","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD000209.pub3-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1192\/bjp.157.4.585","article-title":"Predictors of improvement in tardive dyskinesia following discontinuation of neuroleptic medication","volume":"157","author":"Glazer","year":"1990","journal-title":"British Journal of Psychiatry"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD000209.pub3-BIB0068|cit68","first-page":"21","article-title":"Expected incidence of tardive dyskinesia associated with atypical antipsychotics","volume":"61","author":"Glazer","year":"2000","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD000209.pub3-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/oxfordjournals.aje.a009904","article-title":"Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994","volume":"149","author":"Gulliford","year":"1999","journal-title":"American Journal of Epidemiology"},{"key":"10.1002\/14651858.CD000209.pub3-BIB0070|cit70","volume-title":"ECDEU Assessment Manual for Psychopharmacology. Revised Edition","author":"Guy","year":"1976"},{"issue":"1","key":"10.1002\/14651858.CD000209.pub3-BIB0071|cit71","first-page":"35","article-title":"Successful prevention of tardive dyskinesia","volume":"4","author":"Hawkins","year":"1989","journal-title":"Journal of Orthomolecular Medicine"},{"key":"10.1002\/14651858.CD000209.pub3-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD000209.pub3-BIB0073|cit73","unstructured":"Higgins JPT Green S editor(s) Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S, editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.handbook.cochrane.org"},{"key":"10.1002\/14651858.CD000209.pub3-BIB0074|cit74","unstructured":"Higgins JPT Altman DG Sterne JAC editor(s) Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.handbook.cochrane.org"},{"issue":"2","key":"10.1002\/14651858.CD000209.pub3-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1093\/schbul\/19.2.303","article-title":"Tardive dyskinesia","volume":"19","author":"Jeste","year":"1993","journal-title":"Schizophrenia Bulletin"},{"issue":"7303","key":"10.1002\/14651858.CD000209.pub3-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1136\/bmj.323.7303.42","article-title":"Systematic reviews in health care: assessing the quality of controlled clinical trials","volume":"323","author":"J\u0171ni","year":"2001","journal-title":"BMJ (Clinical research ed.)"},{"key":"10.1002\/14651858.CD000209.pub3-BIB0077|cit77","volume-title":"Positive and Negative Syndrome Scale (PANSS) Manual","author":"Kay","year":"1986"},{"issue":"11","key":"10.1002\/14651858.CD000209.pub3-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.biopsych.2005.10.020","article-title":"Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology","volume":"59","author":"Leon","year":"2006","journal-title":"Biological Psychiatry"},{"issue":"2-3","key":"10.1002\/14651858.CD000209.pub3-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"What does the PANSS mean?","volume":"79","author":"Leucht","year":"2005","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD000209.pub3-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1192\/bjp.187.4.366","article-title":"Clinical implications of Brief Psychiatric Rating Scale scores","volume":"187","author":"Leucht","year":"2005","journal-title":"British Journal of Psychiatry"},{"issue":"2-3","key":"10.1002\/14651858.CD000209.pub3-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"What does the PANSS mean?","volume":"79","author":"Leucht","year":"2005","journal-title":"Schizophrenia Research"},{"issue":"1","key":"10.1002\/14651858.CD000209.pub3-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/schbul\/sbl025","article-title":"Is the superior efficacy of new generation antipsychotics an artifact of LOCF?","volume":"33","author":"Leucht","year":"2007","journal-title":"Schizophrenia Bulletin"},{"issue":"Supplement 29","key":"10.1002\/14651858.CD000209.pub3-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1192\/S0007125000298255","article-title":"Introduction","volume":"168","author":"Lieberman","year":"1996","journal-title":"British Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD000209.pub3-BIB0084|cit84","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000458.pub2","article-title":"Non-neuroleptic catecholaminergic drugs for neuroleptic induced tardive dyskinesia","author":"Lyra da Silva","year":"1997","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD000209.pub3-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1192\/bjp.176.3.249","article-title":"Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia","volume":"176","author":"Marshall","year":"2000","journal-title":"British Journal of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD000209.pub3-BIB0086|cit86","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000208","article-title":"Miscellaneous treatments for neuroleptic-induced tardive dyskinesia","author":"McGrath","year":"2000","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD000209.pub3-BIB0087|cit87","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000205.pub2","article-title":"Benzodiazepines for neuroleptic-induced tardive dyskinesia","author":"McGrath","year":"2000","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD000209.pub3-BIB0088|cit88","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000459.pub2","article-title":"Neuroleptic reduction and\/or cessation and neuroleptics as specific treatments for tardive dyskinesia","author":"McGrath","year":"2000","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD000209.pub3-BIB0089|cit89","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000207","article-title":"Cholinergic medication for neuroleptic-induced tardive dyskinesia","author":"McGrath","year":"2000","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD000209.pub3-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The Brief Psychiatric Rating Scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychological Reports"},{"key":"10.1002\/14651858.CD000209.pub3-BIB0091|cit91","article-title":"Crossover trials","volume-title":"Clinical trials. A Practical Approach","author":"Pocock","year":"1983"},{"key":"10.1002\/14651858.CD000209.pub3-BIB0092|cit92","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2008"},{"issue":"1-2","key":"10.1002\/14651858.CD000209.pub3-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0952-3278(96)90149-0","article-title":"Antioxidant treatment of tardive dyskinesia","volume":"55","author":"Rotrosen","year":"1996","journal-title":"Prostaglandins, Leukotrienes and Essential Fatty Acids"},{"key":"10.1002\/14651858.CD000209.pub3-BIB0094|cit94","first-page":"431","article-title":"The clinical research base for the treatment of schizophrenia","volume":"29","author":"Schooler","year":"1993","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1002\/14651858.CD000209.pub3-BIB0095|cit95","unstructured":"Sch\u00fcnemann HJ Oxman AD Vist GE Higgins JPT Deeks JJ Glasziou P Chapter 12: Interpreting results and drawing conclusions. In Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD000209.pub3-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"2","key":"10.1002\/14651858.CD000209.pub3-BIB0097|cit97","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000206","article-title":"Diltiazem, nifedipine, nimodipine or verapamil for neuroleptic-induced tardive dyskinesia","author":"Soares","year":"2000","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD000209.pub3-BIB0098|cit98","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000204","article-title":"Anticholinergic medication for neuroleptic-induced tardive dyskinesia","author":"Soares","year":"2000","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD000209.pub3-BIB0099|cit99","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000203.pub2","article-title":"Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia","author":"Soares","year":"2000","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD000209.pub3-BIB0100|cit100","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000203.pub2","article-title":"Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia","author":"Soares","year":"2001","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD000209.pub3-BIB0101|cit101","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000206.pub2","article-title":"Calcium channel blockers for neuroleptic-induced tardive dyskinesia","author":"Soares","year":"2001","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD000209.pub3-BIB0102|cit102","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000204","article-title":"Anticholinergic medication for neuroleptic-induced tardive dyskinesia","author":"Soares-Weiser","year":"1997","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD000209.pub3-BIB0103|cit103","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000208","article-title":"Miscellaneous treatments for neuroleptic-induced tardive dyskinesia","author":"Soares-Weiser","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD000209.pub3-BIB0104|cit104","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000459.pub2","article-title":"Neuroleptic reduction and\/or cessation and neuroleptics as specific treatments for tardive dyskinesia","author":"Soares-Weiser","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD000209.pub3-BIB0105|cit105","unstructured":"Sterne JAC Egger M Moher D editor(s) Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.handbook.cochrane.org"},{"issue":"3","key":"10.1002\/14651858.CD000209.pub3-BIB0106|cit106","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000207","article-title":"Cholinergic medication for neuroleptic-induced tardive dyskinesia","author":"Tammenmaa","year":"2002","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD000209.pub3-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta3050","article-title":"Methods for evaluating area-wide and organistation-based intervention in health and health care: a systematic review","volume":"3","author":"Ukoumunne","year":"1999","journal-title":"Health Technology Assessment"},{"issue":"2","key":"10.1002\/14651858.CD000209.pub3-BIB0108|cit108","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000205.pub2","article-title":"Benzodiazepines for neuroleptic-induced tardive dyskinesia","author":"Umbrich","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD000209.pub3-BIB0109|cit109","unstructured":"Xia J Adams CE Bhagat N Bhagat V Bhoopathi P Pinfold V The Leeds Outcomes Stakeholders Survey (LOSS) Study Proceedings of the 15th Cochrane Colloquium; 2007 Oct 23-27, Sao Paulo Sao Paulo 2007"},{"issue":"7","key":"10.1002\/14651858.CD000209.pub3-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1192\/pb.bp.108.021949","article-title":"Loss to outcomes stakeholder survey: the LOSS study","volume":"33","author":"Xia","year":"2009","journal-title":"Psychiatric Bulletin"},{"issue":"4","key":"10.1002\/14651858.CD000209.pub3-BIB0111|cit111","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000209","article-title":"Vitamin E for neuroleptic-induced tardive dyskinesia","author":"McGrath","year":"2001","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD000209.pub3-BIB0112|cit112","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000209","article-title":"Vitamin E for neuroleptic-induced tardive dyskinesia","author":"Soares","year":"1999","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD000209.pub3-BIB0113|cit113","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000209","article-title":"Vitamin E for neuroleptic-induced tardive dyskinesia","author":"Soares","year":"2000","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD000209.pub3-BIB0114|cit114","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000209.pub2","article-title":"Vitamin E for neuroleptic-induced tardive dyskinesia","author":"Soares-Weiser","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD000209.pub3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,7]],"date-time":"2022-01-07T08:47:50Z","timestamp":1641545270000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD000209.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Schizophrenia Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2018,1,17]]},"references-count":114,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2019,9]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd000209.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,17]]}}}